 | | Vol. 13.40 – 11 October, 2022 |
| |
|
|
| The authors showed that matrix-metalloprotease-cleaved type I collagen (Col I) and intact Col I exerted opposing effects on PDAC bioenergetics, macropinocytosis, tumour growth and metastasis.
[Nature] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists studied whether PPP3/calcineurin inhibitors could affect the mitophagy of pancreatic β-cells and pancreatic β-cell function by employing FK506, an immunosuppressive drug against graft rejection.
[Autophagy] |
|
|
|
| Researchers described the involvement of the RNA binding protein hnRNPA2B1 in the development of hypertriglyceridemia-induced acute pancreatitis (HTGP). They used palmitic acid and AR42J cells to create a model of HTGP in vitro.
[Cell Death & Disease] |
| |
|
|
| MRTX1133 exhibited dose-dependent inhibition of KRAS-mediated signal transduction and marked tumor regression in a subset of KRASG12D-mutant cell-line-derived and patient-derived xenograft models, including eight of 11 PDAC models.
[Nature Medicine] |
|
|
|
| Gemcitabine significantly increased the mRNA and protein levels of endoplasmic reticulum aminopeptidase 2 (ERAP2) in pancreatic cancer cells. Additionally, ERAP2 knockdown suppressed tumorigenesis and potentiated gemcitabine-induced growth, migration and invasion inhibition in human pancreatic cancer cells.
[Aging] |
|
|
|
| Scientists provided evidence of a SMAD2/3 oncogenic effect in response to TGF-β1 in SMAD4-null human PDAC cancer cells, reporting that inactivation of SMAD2/3 in SMAD4-negative PDAC cells compromised TGF-β-driven collective migration mediated by FAK and Rho/Rac signaling.
[Communications Biology] |
|  |
|
|
|
| Investigators summarize the state of human pluripotent stem cell differentiation approaches to generate cell types and tissues relevant to type 1 diabetes with a particular focus on pancreatic islet cells, T cells, and thymic epithelium.
[Molecular Metabolism] |
|
|
|
|
| Researchers have begun recruiting volunteers for a clinical trial to study the effectiveness of a combination therapy for patients with pancreatic adenocarcinoma. Patients with early-stage pancreatic cancer and who have had no prior chemotherapy or radiation may be eligible for the study.
[Baylor College of Medicine] |
|
|
|
|
| November 7 – 9, 2022
Singapore, Singapore |
|
|
|
|
|
| | University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
| | The University of Massachusetts Chan Medical School – Worcester, Massachusetts, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Max Delbrück Center for Molecular Medicine – Berlin, Germany |
|
|
|
| | University of Illinois Chicago – Chicago, Illinois, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
